Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Dare Bioscience (DARE) over the last 11 years, with Q3 2025 value amounting to $21.2 million.

  • Dare Bioscience's Total Current Liabilities rose 6127.12% to $21.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.2 million, marking a year-over-year increase of 6127.12%. This contributed to the annual value of $21.6 million for FY2024, which is 553.03% up from last year.
  • As of Q3 2025, Dare Bioscience's Total Current Liabilities stood at $21.2 million, which was up 6127.12% from $19.2 million recorded in Q2 2025.
  • Dare Bioscience's 5-year Total Current Liabilities high stood at $31.6 million for Q4 2022, and its period low was $6.0 million during Q2 2021.
  • Its 5-year average for Total Current Liabilities is $18.7 million, with a median of $19.2 million in 2025.
  • In the last 5 years, Dare Bioscience's Total Current Liabilities skyrocketed by 17539.12% in 2022 and then plummeted by 5005.94% in 2024.
  • Over the past 5 years, Dare Bioscience's Total Current Liabilities (Quarter) stood at $16.1 million in 2021, then skyrocketed by 97.0% to $31.6 million in 2022, then crashed by 35.24% to $20.5 million in 2023, then increased by 5.53% to $21.6 million in 2024, then fell by 1.84% to $21.2 million in 2025.
  • Its Total Current Liabilities stands at $21.2 million for Q3 2025, versus $19.2 million for Q2 2025 and $21.2 million for Q1 2025.